Chemomab Therapeutics (NASDAQ:CMMB) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Chemomab Therapeutics (NASDAQ:CMMB) to a hold rating in a report published on Saturday.

CMMB has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Chemomab Therapeutics in a research report on Wednesday. Oppenheimer boosted their target price on shares of Chemomab Therapeutics from $10.00 to $25.00 and gave the company an “outperform” rating in a research note on Wednesday, August 27th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Chemomab Therapeutics has an average rating of “Hold” and an average target price of $26.50.

Chemomab Therapeutics Price Performance

NASDAQ:CMMB opened at $3.28 on Friday. Chemomab Therapeutics has a 1-year low of $2.39 and a 1-year high of $9.84. The firm has a 50-day moving average of $3.21 and a two-hundred day moving average of $4.24. The stock has a market cap of $16.96 million, a P/E ratio of -1.39 and a beta of 0.57.

Chemomab Therapeutics (NASDAQ:CMMB) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.44. As a group, equities analysts expect that Chemomab Therapeutics will post -1 earnings per share for the current year.

Hedge Funds Weigh In On Chemomab Therapeutics

A hedge fund recently raised its stake in Chemomab Therapeutics stock. Virtu Financial LLC raised its position in shares of Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) by 113.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,803 shares of the company’s stock after purchasing an additional 16,358 shares during the quarter. Virtu Financial LLC owned 0.21% of Chemomab Therapeutics worth $34,000 at the end of the most recent quarter. 46.05% of the stock is owned by institutional investors.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).